same stuff we already know, although dr. D did say we would be hearing news about the pipeline in the next couple months (who knows what that means?). and again he pumped the GPCR platform as usual.
in the meantime, amgn loses big time on enbrel to other biosimilars - you forget to mention that.
actually, wbb was part of a refi a year or so ago, and they received shares, hence they apply a huge pt so they can sell.
that even beats the 62. pt that use to be the highest
what am i missing here ? listened to the asco/investor conf - the docs and data sound great. the q&a session was very revealing when the docs spoke.
Seems kind of fishy....